243.09
price down icon0.66%   -1.61
after-market Handel nachbörslich: 246.90 3.81 +1.57%
loading
Schlusskurs vom Vortag:
$244.70
Offen:
$245.74
24-Stunden-Volumen:
737.77K
Relative Volume:
0.72
Marktkapitalisierung:
$35.70B
Einnahmen:
$5.02B
Nettoeinkommen (Verlust:
$1.31B
KGV:
27.28
EPS:
8.91
Netto-Cashflow:
$1.56B
1W Leistung:
+2.79%
1M Leistung:
+18.85%
6M Leistung:
-3.68%
1J Leistung:
+14.19%
1-Tages-Spanne:
Value
$242.77
$247.35
1-Wochen-Bereich:
Value
$237.00
$247.35
52-Wochen-Spanne:
Value
$179.42
$263.05

Resmed Inc Stock (RMD) Company Profile

Name
Firmenname
Resmed Inc
Name
Telefon
(858) 746-2400
Name
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Name
Mitarbeiter
9,980
Name
Twitter
@resmed
Name
Nächster Verdiensttermin
2024-10-24
Name
Neueste SEC-Einreichungen
Name
RMD's Discussions on Twitter

Vergleichen Sie RMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Instruments & Supplies icon
RMD
Resmed Inc
243.09 35.70B 5.02B 1.31B 1.56B 8.91
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
538.16 185.37B 8.71B 2.48B 1.75B 6.82
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
167.95 48.59B 20.87B 1.50B 2.59B 5.24
Medical Instruments & Supplies icon
ALC
Alcon Inc
95.88 47.57B 9.91B 1.02B 665.00M 2.05
Medical Instruments & Supplies icon
COO
The Cooper Companies, Inc.
82.92 16.51B 3.90B 392.30M 288.10M 1.95

Resmed Inc Stock (RMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-19 Eingeleitet Morgan Stanley Overweight
2025-01-16 Eingeleitet Goldman Buy
2025-01-10 Eingeleitet Piper Sandler Neutral
2024-12-13 Eingeleitet Stifel Hold
2024-09-24 Eingeleitet Robert W. Baird Outperform
2024-09-18 Herabstufung Wolfe Research Peer Perform → Underperform
2024-09-04 Herabstufung Needham Buy → Hold
2024-06-25 Herabstufung Oppenheimer Outperform → Perform
2024-06-24 Herabstufung Citigroup Buy → Neutral
2024-02-06 Fortgesetzt KeyBanc Capital Markets Overweight
2023-10-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-10-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-10-09 Hochstufung JP Morgan Neutral → Overweight
2023-09-29 Herabstufung Wolfe Research Outperform → Peer Perform
2023-09-06 Hochstufung Needham Hold → Buy
2023-09-05 Herabstufung UBS Buy → Neutral
2023-08-01 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-05-23 Eingeleitet UBS Buy
2023-04-14 Eingeleitet Mizuho Buy
2023-01-17 Hochstufung JP Morgan Neutral → Overweight
2022-10-28 Herabstufung Citigroup Buy → Neutral
2022-10-20 Hochstufung BofA Securities Neutral → Buy
2022-10-12 Eingeleitet Jefferies Hold
2022-09-08 Hochstufung Citigroup Neutral → Buy
2022-08-15 Herabstufung CLSA Buy → Outperform
2022-08-12 Herabstufung Citigroup Buy → Neutral
2022-08-12 Herabstufung JP Morgan Overweight → Neutral
2022-08-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-06-06 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-04-06 Eingeleitet Wolfe Research Outperform
2022-01-31 Hochstufung Citigroup Neutral → Buy
2022-01-31 Hochstufung Goldman Neutral → Buy
2022-01-28 Hochstufung RBC Capital Mkts Underperform → Sector Perform
2022-01-24 Hochstufung BofA Securities Underperform → Neutral
2022-01-24 Hochstufung JP Morgan Neutral → Overweight
2022-01-13 Hochstufung CLSA Outperform → Buy
2022-01-13 Hochstufung Robert W. Baird Neutral → Outperform
2021-12-21 Hochstufung KeyBanc Capital Markets Sector Weight → Overweight
2021-12-06 Hochstufung Macquarie Neutral → Outperform
2021-10-22 Hochstufung CLSA Underperform → Outperform
2021-08-02 Herabstufung CLSA Outperform → Sell
2021-08-02 Herabstufung Needham Buy → Hold
2021-07-28 Hochstufung Jefferies Underperform → Hold
2021-07-26 Herabstufung JP Morgan Overweight → Neutral
2021-07-14 Eingeleitet RBC Capital Mkts Underperform
2021-06-28 Herabstufung Citigroup Buy → Neutral
2021-06-22 Hochstufung Macquarie Neutral → Outperform
2021-06-22 Eingeleitet Robert W. Baird Neutral
2021-06-21 Bestätigt Needham Buy
2021-06-16 Herabstufung BofA Securities Neutral → Underperform
2021-06-09 Hochstufung CLSA Sell → Outperform
2021-05-21 Hochstufung JP Morgan Neutral → Overweight
2021-05-11 Hochstufung Citigroup Neutral → Buy
2021-04-30 Herabstufung Citigroup Buy → Neutral
2021-03-16 Hochstufung Needham Hold → Buy
2020-11-02 Hochstufung UBS Neutral → Buy
2020-10-30 Hochstufung JP Morgan Underweight → Neutral
2020-10-27 Hochstufung BofA Securities Underperform → Neutral
2020-08-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-06-17 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-05-01 Herabstufung JP Morgan Neutral → Underweight
2020-05-01 Hochstufung Oppenheimer Perform → Outperform
2020-02-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-02-03 Eingeleitet CLSA Underperform
2020-01-31 Herabstufung UBS Buy → Neutral
2020-01-10 Eingeleitet Oppenheimer Perform
2019-11-22 Eingeleitet KeyBanc Capital Markets Sector Weight
2019-07-29 Hochstufung UBS Neutral → Buy
2019-07-16 Herabstufung UBS Buy → Neutral
2019-05-06 Hochstufung UBS Neutral → Buy
2019-04-18 Hochstufung JP Morgan Underweight → Neutral
2019-01-25 Herabstufung Goldman Buy → Neutral
2019-01-25 Herabstufung JP Morgan Neutral → Underweight
2018-10-26 Hochstufung Credit Suisse Neutral → Outperform
2018-07-02 Eingeleitet Goldman Buy
Alle ansehen

Resmed Inc Aktie (RMD) Neueste Nachrichten

pulisher
May 08, 2025

Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Resmed prevails over Cleveland Medical in CPAP patent review - BioWorld MedTech

May 07, 2025
pulisher
May 06, 2025

Is ResMed Inc.'s (NYSE:RMD) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st

May 06, 2025
pulisher
May 06, 2025

Ex-Dividend Reminder: Seaboard, KB Home and ResMed - Nasdaq

May 06, 2025
pulisher
May 05, 2025

ResMed Inc Reports Changes in CDIs and Securities for April 2025 - TipRanks

May 05, 2025
pulisher
May 05, 2025

Jim Cramer on Viemed Healthcare (VMD): “Interesting, But I’m a ResMed Guy” - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News

May 05, 2025
pulisher
May 03, 2025

Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance

May 03, 2025
pulisher
May 02, 2025

ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma

May 02, 2025
pulisher
May 02, 2025

Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive

May 02, 2025
pulisher
May 02, 2025

This ResMed Insider Reduced Their Stake By 72% - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

Resmed acquires independent diagnostic testing facility VirtuOx - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Resmed Acquires Virtual Care Company VirtuOx - Medical Product Outsourcing

May 01, 2025
pulisher
May 01, 2025

ResMed (RMD) Expands with VirtuOx Acquisition - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Resmed Acquires VirtuOx - Nasdaq

May 01, 2025
pulisher
May 01, 2025

ResMed Buys VirtuOx for Undisclosed sum - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Sto - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Resmed acquires virtual diagnostics company VirtuOx - MassDevice

May 01, 2025
pulisher
May 01, 2025

Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

ResMed announces it has acquired VirtuOx - TipRanks

May 01, 2025
pulisher
Apr 30, 2025

Resmed Inc (RMD): Jim Cramer Says “Remarkable Stock” — Did GLP-1 Drugs Just Hand It a Lifeline? - Insider Monkey

Apr 30, 2025
pulisher
Apr 29, 2025

This ASX medical device company has a Trump tariff exemption - MSN

Apr 29, 2025
pulisher
Apr 29, 2025

Resmed Hires Chief Investor Relations Officer - HME Business

Apr 29, 2025
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 28, 2025

ResMed Inc. Files Quarterly Report, Reinforces Market Position - MSN

Apr 28, 2025
pulisher
Apr 27, 2025

ASX healthcare leader continues to prove the doubters wrong - Morningstar

Apr 27, 2025
pulisher
Apr 27, 2025

What does Macquarie think ResMed shares are worth? - MSN

Apr 27, 2025
pulisher
Apr 27, 2025

ResMed brushes off tariff threat - Intelligent Investor

Apr 27, 2025
pulisher
Apr 27, 2025

ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market - MSN

Apr 27, 2025
pulisher
Apr 27, 2025

ResMed Q1 2025: Strong Sales Growth and Strategic InitiativesNews and Statistics - IndexBox

Apr 27, 2025
pulisher
Apr 26, 2025

ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Call Transcript - Insider Monkey

Apr 26, 2025
pulisher
Apr 25, 2025

ResMed Inc’s Earnings Call Highlights Growth and Innovation - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Compet - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance

Apr 25, 2025
pulisher
Apr 25, 2025

Decoding ResMed Inc (RMD): A Strategic SWOT Insight - GuruFocus

Apr 25, 2025
pulisher
Apr 24, 2025

ResMed Inc. stock rises Thursday, outperforms market - MSN

Apr 24, 2025
pulisher
Apr 24, 2025

ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price ForecastResMed (NYSE:RMD) - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

ResMed (NYSE:RMD) Reports Strong Q3 Earnings Growth and Declares US$0.53 Dividend - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates - MSN

Apr 24, 2025
pulisher
Apr 24, 2025

ResMed Inc (RMD) Shares Up 11.28% on Apr 24 - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

ResMed price target raised to $255 from $247 at RBC Capital - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

Jefferies Adjusts Price Target on ResMed to $245 From $270, Maintains Hold Rating - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Morgan Stanley Adjusts Price Target on ResMed to $286 From $280, Maintains Overweight Rating - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

ResMed stock holds as Oppenheimer maintains Perform rating By Investing.com - Investing.com Canada

Apr 24, 2025
pulisher
Apr 24, 2025

Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On ThursdayArdagh Metal Packaging (NYSE:AMBP), Allegion (NYSE:ALLE) - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Stifel maintains ResMed stock hold rating and $240 target - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Stifel maintains ResMed stock hold rating and $240 target By Investing.com - Investing.com UK

Apr 24, 2025
pulisher
Apr 24, 2025

ResMed stock price target raised to $255 at RBC Capital - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Piper Sandler cuts ResMed stock price target to $248 - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Piper Sandler cuts ResMed stock price target to $248 By Investing.com - Investing.com UK

Apr 24, 2025

Finanzdaten der Resmed Inc-Aktie (RMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
medical_instruments_supplies ALC
$95.88
price down icon 0.23%
medical_instruments_supplies BDX
$167.95
price up icon 0.48%
medical_instruments_supplies COO
$82.92
price up icon 2.06%
medical_instruments_supplies BAX
$31.20
price up icon 1.56%
medical_instruments_supplies WST
$214.74
price up icon 0.75%
Kapitalisierung:     |  Volumen (24h):